IP Library Granted Patent US 11,884,697
Granted Patent B2
US 11,884,697 · App. 17/242,860 · Granted Jan 30, 2024

Oxysterols and methods of use thereof

Inventors: Albert Jean Robichaud (Boston, MA); Francesco G. Salituro (Marlborough, MA); Gabriel Martinez Botella (Wayland, MA); Boyd L. Harrison (Princeton Junction, NJ); John Gregory Reid (Wellington, FL)
Assignee: Sage Therapeutics, Inc.
C07J9/00A61K31/57C07J17/00C07J43/003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,884,697
App. No.
17/242,860
Granted
Jan 30, 2024
Kind
B2
Abstract

Compounds are provided according to Formula (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein A, R 1 , and R 5 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Claims (40)

1. A compound of Formula (I-B):

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is hydrogen or substituted or unsubstituted C 1-6 alkyl;

R 5 is absent or hydrogen;

Z is —C(R A ) 2 —, —NR B —, —O—, or —S—;

X is halogen, substituted or unsubstituted C 1-6 alkyl, or —OR C ;

R A is hydrogen, halogen, or substituted or unsubstituted C 1-6 alkyl;

R B is hydrogen, substituted or unsubstituted C 1-6 alkyl, —C(O)R C , —C(O)OR C , —C(O)N(R D ) 2 , or —S(O) 2 R C ;

R C is hydrogen or substituted or unsubstituted C 1-6 alkyl;

each R D is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

m is an integer selected from 1, 2, and 3;

n is an integer selected from 1, 2, and 3;

p is an integer selected from 0, 1, 2, 3, 4, and 5; and

represents a single or double bond, wherein when one is a double bond, then the other is a single bond and R 5 is absent.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (II-A), Formula (II-B), or Formula (II-C):

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein p is an integer selected from 0, 1, or 2.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein p is 0.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein p is 1.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein p is 1 and X is halogen.

7. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (II-D), Formula (II-E), or Formula (II-F):

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is substituted or unsubstituted C 1-6 alkyl.

9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 1 is methyl or ethyl.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (II-G) or Formula (II-H):

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (II-I) or Formula (II-J):

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is —C(R A ) 2 —, —O—, or —NR B —.

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R A is halogen.

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is —CH 2 —, —CF 2 —, or —C(CH 3 ) 2 —.

15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —NR B —.

16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is —NH—, —NCH 3 —, or —NC(O)CH 3 —.

17. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is —CH 2 —.

18. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is —C(CH 3 ) 2 —.

19. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is —CF 2 —.

20. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1, n is 2, and Z is —O—.

21. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 2 and n is 2.

22. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 3 and n is 1.

23. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 3, n is 1, and Z is —O—.

24. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 2, n is 2, and Z is —O— or —NR B —.

25. A compound selected from:

26. A pharmaceutically acceptable salt of a compound selected from:

27. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2025
From: ROBICHAUD, ALBERT JEAN; BOTELLA, GABRIEL MARTINEZ; SALITURO, FRANCESCO G.; HARRISON, BOYD L.; REID, JOHN GREGORY
To: SAGE THERAPEUTICS, INC.
Reel/Frame 071510/0888 →
Continuity (3)
Continuation 16089896
Provisional Application 62317002 · Apr 1, 2016
Related Publication 20210261598A1 · Aug 26, 2021
Cited By (3)
US 12,331,070 US 12,448,409 US 12,540,157